Logo

Iconix Signs Chemogenomics Collaboration with Icos

Jun 24, 2004

NEW YORK, June 24 (GenomeWeb News) - Iconix Pharmaceuticals will provide its chemogenomic profiling technology to Icos, the Mountain View, Calif.-based company said today.

 

Under the agreement, Icos will use Iconix's chemogenomics platform to study preclinical drug responses and to discover biomarkers to predict drug efficacy and side effects.

 

Iconix will use its Drug Signature collection of predictive biomarkers, derived from its DrugMatrix chemogenomics reference database.

Breaking News
The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.